Capsule Slidesets

Share

Program Content

Activities

  • FLYER: R-CHOP x 4 → R x 2 in DLBCL
    FLYER: Phase III Trial of R-CHOP x 4 Followed by Rituximab x 2 vs R-CHOP x 6 in Younger Patients With Favorable-Prognosis DLBCL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 03, 2018

    Expires: December 02, 2019

  • KEYNOTE-170/-013: Pembrolizumab in R/R PMBCL
    Phase II KEYNOTE-170/KEYNOTE-013 Update: Pembrolizumab in Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 06, 2018

    Expires: December 05, 2019

  • Rituximab Biosimilar in FL
    REFLECTIONS: Phase III Study of Rituximab Biosimilar PF-05280586 vs Reference Rituximab in Untreated CD20+ Follicular Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 06, 2018

    Expires: December 05, 2019

  • E1912: Ibrutinib + Rituximab in CLL
    Phase III E1912: First-line Ibrutinib + Rituximab vs Standard-of-Care FCR in Younger Patients With Previously Untreated CLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 07, 2018

    Expires: December 06, 2019

  • ROAR: BRAFi + MEKi in R/R HCL
    ROAR: Phase II Study of Dabrafenib + Trametinib for Relapsed/Refractory BRAF V600E–Mutated Hairy Cell Leukemia
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 10, 2018

    Expires: December 09, 2019

  • ECHELON-2: BV + CHP in PTCL
    ECHELON-2: Phase III Trial of Brentuximab Vedotin + CHP vs CHOP in Previously Untreated CD30+ Peripheral T-Cell Lymphomas
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 11, 2018

    Expires: December 10, 2019

  • Ibrutinib + Venetoclax in CLL
    Phase II Trial of Ibrutinib + Venetoclax in Previously Untreated, High-Risk Chronic Lymphocytic Leukemia (CLL)
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2018

    Expires: December 11, 2019

  • Ibrutinib + R-CHOP in Non-GCB DLBCL
    Phase III Trial of First-line Ibrutinib + R-CHOP vs Placebo + R-CHOP in Patients With Non–Germinal Center B-Cell Subtypes of DLBCL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2018

    Expires: December 13, 2019

  • iLLUMINATE: Ibrutinib + Obinutuzumab in CLL/SLL
    iLLUMINATE: Phase III Trial of Ibrutinib + Obinutuzumab vs Chlorambucil + Obinutuzumab in Previously Untreated CLL/SLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2018

    Expires: December 16, 2019

  • ACE-CL-001: Acalabrutinib in CLL
    ACE-CL-001 Updated Analysis: Phase I/II Study of Frontline Acalabrutinib in Chronic Lymphocytic Leukemia
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 18, 2018

    Expires: December 17, 2019

  • ZUMA-1: Axi-cel in R/R Large BCL
    Axicabtagene Ciloleucel in Patients With Refractory Large B-Cell Lymphoma: Extended 2-Yr Follow-up of Phase II ZUMA-1 Trial
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 14, 2019

    Expires: March 12, 2020

  • PET-Guided Tx in DLBCL
    Intergroup NCTN Study S1001: PET-Directed Therapy in Limited-Stage DLBCL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 19, 2019

    Expires: December 17, 2020

  • Ibrutinib ± R vs BR in Older CLL Patients
    A041202: Phase III Trial of Ibrutinib ± Rituximab vs Bendamustine + Rituximab in Older Patients With Previously Untreated CLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022
  • AUGMENT: R² in iNHL
    AUGMENT: Phase III Study of Rituximab/Lenalidomide vs Rituximab/Placebo for R/R Indolent Non-Hodgkin Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

Provided by

ProCE Banner

Supporters

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology